Finasteride vs. Dutasteride for Hair Loss: Efficacy, Side Effects, and Cost

Finasteride and dutasteride are both 5-alpha-reductase inhibitors used for male androgenetic alopecia, but they differ in a critical way: finasteride selectively inhibits only Type II 5-alpha-reductase, while dutasteride inhibits both Type I and Type II, producing more complete DHT suppression. Dutasteride is FDA-approved only for BPH; its use for AGA is off-label in the US, but it is approved for AGA in Japan (2015) and South Korea (2009).

Head-to-Head Comparison

	Finasteride 1 mg	Dutasteride 0.5 mg
5-AR isoforms inhibited	Type II only	Type I and Type II (dual)
Serum DHT suppression	~65-70%	~90-95%
Scalp DHT suppression	~64%	~79%
FDA approval for AGA	Yes (1997)	No (off-label in US)
FDA approval for BPH	Yes (1992)	Yes (2001)
AGA-specific approval outside US	N/A	Japan (2015), South Korea (2009)
Evidence base for AGA	25+ years; multiple large RCTs	Several RCTs; largest is Gubelin Harcha 2014, n=917
Hair count improvement vs. finasteride	Reference	Numerically superior in head-to-head trials
Plasma half-life	6-8 hours	~5 weeks (much longer)
Monthly cost (generic)	$15, $35	$30, $60 (less available in 0.5 mg; often sourced as BPH dose)
Sexual side effect risk	~1-2% excess over placebo	Likely slightly higher due to greater DHT suppression

Efficacy Evidence: Does Dutasteride Work Better?

The most rigorous head-to-head comparison is the Olsen et al. 2006 randomized trial (n=416 men with AGA; 24 weeks): dutasteride 2.5 mg produced significantly greater hair count gains than finasteride 5 mg at 12 and 24 weeks.

The largest head-to-head trial is Gubelin Harcha et al. 2014 (J Am Acad Dermatol), a randomized, active- and placebo-controlled study in which 917 men with AGA received dutasteride 0.02, 0.1 or 0.5 mg daily, finasteride 1 mg daily or placebo for 24 weeks. Dutasteride 0.5 mg increased hair count and hair width significantly more than finasteride 1 mg at week 24 (P = .003 and P = .004), and the number and severity of adverse events were similar across the treatment groups.

Key Trials

Study	Design	n	Duration	Outcome
Olsen EA, et al. 2006	Double-blind RCT; dutasteride 0.05, 0.1, 0.5, 2.5 mg vs. finasteride 5 mg vs. placebo	416	24 weeks	Dutasteride 2.5 mg produced significantly greater hair count increases than finasteride 5 mg at 12 and 24 weeks; dutasteride 0.5 mg was the approved dose in South Korea/Japan
Gubelin Harcha W, et al. 2014	Multicenter, double-blind RCT	917	24 weeks	Dutasteride 0.5 mg superior to finasteride 1 mg for total and target area hair count; statistically significant at 24 weeks

Which Should You Choose?

Scenario	Consider
First-line AGA treatment; want FDA-approved option	Finasteride 1 mg
Partial or inadequate response to finasteride after 12-18 months	Physician discussion about switching to dutasteride
Rapid or severe AGA progression; willing to accept off-label use	Dutasteride (off-label); discuss with dermatologist
Concerned about side effects; prefer less aggressive DHT suppression	Finasteride 1 mg (lower DHT suppression = potentially less risk)
Needing a drug with shortest half-life for reversibility	Finasteride (clears in days vs. dutasteride’s weeks-long washout)

Key Practical Differences

Half-life matters for discontinuation: Finasteride’s short half-life (~6 hours) means DHT levels recover within days of stopping. Dutasteride’s very long half-life (~5 weeks) means serum dutasteride persists for months after the last dose, and DHT suppression continues for 4-6 months after stopping. This has implications for men who want to trial a drug, stop it, or father children. Stopping dutasteride does not rapidly clear the drug as stopping finasteride does.

Fertility: Both finasteride and dutasteride reduce ejaculate volume and may affect semen parameters (sperm count, motility). Dutasteride’s longer persistence means its effects on semen persist longer after stopping. Men planning conception should discuss both drugs with a urologist.

Frequently Asked Questions

Can I switch from finasteride to dutasteride?

Yes, switching is possible and is done clinically in men who have had inadequate response to finasteride. Because dutasteride is off-label for AGA in the US, this requires a physician prescribing it off-label. You do not need to wean off finasteride before starting dutasteride. Some dermatologists will switch men who respond but progress on finasteride, or who are willing to accept greater DHT suppression for potentially better results.

Is dutasteride safe to use off-label for hair loss?

Dutasteride has a well-characterized safety profile from its approved BPH indication (Avodart). Its use for AGA is off-label in the US but supported by clinical trial data and approved in two countries for that indication. The main safety considerations are the same as finasteride, sexual side effects, potential PFS-type persistent effects, and teratogenicity (Pregnancy Category X), with potentially higher rates due to greater DHT suppression. Discuss risks and benefits with a physician who can review your individual clinical profile.

Sources

• Olsen EA, et al. “The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.” J Am Acad Dermatol. 2006;55(6):1014-1023.
• Gubelin Harcha W, et al. “A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects.” J Am Acad Dermatol. 2014;70(3):489-498.
• Merck & Co. Propecia US Prescribing Information. 2022. GlaxoSmithKline. Avodart (dutasteride) US Prescribing Information. 2021.